The Value of Pelvic Magnetic Resonance Imaging in Detecting Bone Marrow Infiltration of Lymphoma
PMRIL
Bone Marrow Cytology, Pathology and 18F-FDG PET/CT and Pelvic MRI in the Diagnosis of Lymphoma Bone Marrow Invasion
1 other identifier
observational
142
1 country
1
Brief Summary
The diagnosis of lymphoma bone marrow infiltration is very important for the staging and treatment mode of lymphoma. Traditional bone marrow cytology and pathology examinations are only performed locally, and missed diagnosis is possible. The study explore the value of multi-parameter pelvic magnetic resonance in detecting bone marrow infiltration with newly diagnosed lymphoma patients . This study also explore the consistency of pelvic magnetic resonance and PET/CT for detection of lymphoma bone marrow infiltration.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 2, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 22, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
May 22, 2019
CompletedFirst Submitted
Initial submission to the registry
June 1, 2019
CompletedFirst Posted
Study publicly available on registry
June 4, 2019
CompletedJune 4, 2019
June 1, 2019
1.3 years
June 1, 2019
June 3, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Agreement Between MRI and Bone marrow cytology, pathology and follow-up at Diagnosis
MRI-positive lesions that cannot be confirmed by bone marrow cytology and pathology will be confirmed by MRI follow-up.
Within 30 days prior to start of chemotherapy
Secondary Outcomes (1)
Agreement Between MRI and 18F-FDG PET/CT at Diagnosis
Within 30 days prior to start of chemotherapy
Eligibility Criteria
The study population was an Asian race with lymphoma.
You may qualify if:
- Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by are reference pathologist.
- Patients who gave written informed consent were referred for MRI.
- Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging).
You may not qualify if:
- Pregnancy, general contraindications to MRI.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Affiliated Tumor Hospital，Guangxi Medical University
Nanning, China
Related Publications (1)
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014 Sep 20;32(27):3048-58. doi: 10.1200/JCO.2013.53.5229.
PMID: 25113771BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 1, 2019
First Posted
June 4, 2019
Study Start
February 2, 2018
Primary Completion
May 22, 2019
Study Completion
May 22, 2019
Last Updated
June 4, 2019
Record last verified: 2019-06